At a glance
ClinicalIndex Comparison Record- ✓Age 18–65 years
- ✓Diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features (DSM-IV)
- ✓Currently receiving an antipsychotic drug (clozapine, haloperidol, olanzapine, quetiapine, or risperidone) alone, mood stabilizer(s) alone, or both
- ✓History of compliance with psychiatric medications
- ✕Diagnosis other than schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features (DSM-IV)
- ✕History of noncompliance with prescribed psychiatric medications
- ✕Triglyceride/HDL ratio < 3.5 on current medication
- ✕Uninsured or unable to pay out-of-pocket costs for lab procedures not covered by insurance
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
In Brief
A clinical study evaluating ziprasidone vs. aripiprazole and aripiprazole vs. ziprasidone for Schizophrenia and 2 related conditions. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs). Patients will be switched from their current antipsychotic medication to aripiprazole (Abilify) or ziprasidone (Geodon) (unless clinically contraindicated) for comparison with metabolic levels during treatment with the former medication. The metabolic syndrome is an empirical concept based on extensive evidence that a constellation of 5 metabolic abnormalities, e.g. increased cholesterol, hypertension, low HDL, taken together, predict marked increases in the risk of CVD, stroke and some types of cancer.
Study Details
Timeline
Interventions
ziprasidone vs. aripiprazole dosed according to package insert
aripiprazole vs. ziprasidone dosed according to package insert